In this study, we evaluated the immunotherapeutic efficacy of activated NK cells given locally inside tumors, along with strategies that neutralize the NKG2A inhibitory pathway and thereby unleash robust local and systemic adaptive immune responses ultimately capable of better controlling tumor progression. Here, KLRC1 is linked to neoplasm.